Treatment with MaR1 also reduced 2,4,6-trinitrobenzenesulfonic acid- and dextran sulfate sodium-induced inflammatory bowel disease by reducing the production of cytokines such as tumor necrosis factor-α (TNFα), IL-1β, IL-6 and interferon-γ (IFNγ) depending on the stage of the disease. The gene discussed is TNF; the disease is inflammatory bowel disease.